[Press release] UNAIDS strongly welcomes bold, new US funding package for HIV

On 3 February 2026 US President Donald Trump signed a bipartisan consolidated spending package totaling US$5.88 billion that allocates US$4.6 billion for bilateral HIV support under the America First Global Health Strategy, US$1.25 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria, and US$45 million to UNAIDS. The legislation reaffirms continued US fiscal leadership in the global HIV response and is a positive funding development for global-health NGOs and multilateral programmes, though it is unlikely to have material impact on financial markets.

Analysis

Market structure: The $5.88B package (US$4.6B bilateral + US$1.25B Global Fund) is a demand shock concentrated in low-/middle-income procurement for ARVs, PrEP, and diagnostics; beneficiaries are large-volume suppliers (GILD, GSK) and diagnostics leaders (ABT, RHHBY) while high-margin branded pricing power is limited because procurement is price‑sensitive. Competitive dynamics will favor scale/low-cost producers and diagnostics with established tender footprint; expect 3–8% incremental volume for ARVs in 12 months but downward margin pressure of several hundred basis points on tendered branded products.

Risk assessment: Tail risks include a policy reversal post-election, large tender awards to new entrants, or API supply disruptions that could spike lead times >90 days and compress margins; these are low probability but high impact. Time horizons: immediate (0–90 days) for RFPs and disbursement schedules, short-term (3–12 months) for contract delivery and revenue recognition, long-term (2–4 years) for market-share shifts to PrEP injectables and generics. Hidden dependencies: tender award mechanics, local registration, and FX/recipient-country absorption constraints; catalysts include PEPFAR/Global Fund tender publications and bilateral procurement announcements.

Trade implications: Tilt portfolios into large-cap HIV treatment and diagnostics: GILD, GSK, ABT, RHHBY as primary plays (small, staged allocations) and underweight small-cap EM healthcare services. Use relative-value (pair) trades to capture pricing dispersion (branded vs generics). Options: favor 9–12 month call spreads to limit premium outlay around known procurement windows (60–120 days).

Contrarian angles: Consensus may overstate branded upside—historical US-driven funding (2008–2015) increased volumes but accelerated price competition and consolidation; therefore upside for GILD/GSK is capped vs generics. Unintended consequence: diagnostics and logistics providers (cold chain, lab services) can capture outsized margins; monitor tender concentration—if >60% of volume goes to generics, reweight accordingly.

Key Decisions for Investors

• Establish a 2–3% long position in Gilead Sciences (GILD) sized over 30–90 days to capture ARV procurement tailwinds; add on a pullback ≥8%; target +15–20% in 6–12 months, stop-loss at −10%.
• Allocate 1.5–2% long split 50/50 into Abbott Labs (ABT) and Roche (RHHBY) to play diagnostics demand; horizon 3–9 months, take profit at +12% or exit if cumulative announced diagnostic tenders in 90 days < $200M.
• Initiate a pair trade: long GlaxoSmithKline (GSK) 1.5% vs short Viatris (VTRS) 1.5% to express branded PrEP/injectable share gain vs low-margin generics; horizon 6–18 months, unwind if generics win >60% of tenders.
• Buy a 9–12 month call spread on GILD (buy ATM, sell ATM+15%) sized ~0.5% portfolio to capture upside through expected procurement awards (roll/close on RFP results within 60–120 days).
• Contingent trade: If cumulative Global Fund/PEPFAR ARV tenders announced within 60 days exceed $500M and favor low-cost suppliers, establish 1–2% long in Viatris (VTRS) or Teva (TEVA) and reduce GILD exposure by 50%.